|
75 Companies |
|
98 Products |
|
98 Products |
|
91 Mechanisms of Action |
|
4 Trials |
|
908 News |
|
| 12345678910111213...1718» |
- | Enrollment change, Trial withdrawal, Surgery: TEMENDO: Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas (clinicaltrials.gov) - Sep 8, 2023
P4, N=0, Withdrawn, Sponsor: European Association for Endoscopic Surgery
N=120 --> 0 | Suspended --> Withdrawn
- | Trial completion date, Trial primary completion date: Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=234, Recruiting, Sponsor: Samsung Medical Center
N=120 --> 0 | Suspended --> Withdrawn Trial completion date: May 2018 --> May 2024 | Trial primary completion date: May 2018 --> May 2020
- | Phase classification, Surgery: Efficiency of Two Dimensional High Definition vs Three Dimensional Endoscopic Systems in Transanal Endoscopic Surgery (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=36, Completed, Sponsor: Corporacion Parc Tauli
Trial completion date: May 2018 --> May 2024 | Trial primary completion date: May 2018 --> May 2020 Phase classification: P3 --> P=N/A
- | Trial completion, Trial completion date, Trial primary completion date: Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=96, Completed, Sponsor: Yonsei University
Phase classification: P3 --> P=N/A Recruiting --> Completed | Trial completion date: May 2016 --> Jun 2018 | Trial primary completion date: Dec 2015 --> Jun 2018
- | Trial completion, Trial completion date, Trial primary completion date: Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence (clinicaltrials.gov) - Apr 20, 2019
P2/3, N=1108, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Completed | Trial completion date: May 2016 --> Jun 2018 | Trial primary completion date: Dec 2015 --> Jun 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion, Combination therapy: The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=153, Completed, Sponsor: Yonsei University
Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018 Recruiting --> Completed
- | Trial completion, Preclinical, Enrollment change: Optical Polyp Testing for In Vivo Classification (clinicaltrials.gov) - Apr 16, 2019
P=N/A, N=13, Completed, Sponsor: Imperial College London
Recruiting --> Completed Recruiting --> Completed | N=20 --> 13
- | Enrollment change, Trial withdrawal: Quantificational Enhancement Pattern Analysis Using a Novel Software "Vuebox" of Contrast-enhanced Harmonic Endoscopic Ultrasonography for Differential Diagnosis Between Adenomas and Cholesterol Polyps (clinicaltrials.gov) - Mar 18, 2019
P=N/A, N=0, Withdrawn, Sponsor: Yonsei University
Recruiting --> Completed | N=20 --> 13 N=79 --> 0 | Not yet recruiting --> Withdrawn
- ||||||||| cisplatin / Generic mfg., pemetrexed / Generic mfg., nintedanib / Generic mfg.
Phase classification, Trial termination, Combination therapy, Monotherapy: LUME-Meso: Nintedanib (BIBF 1120) in Mesothelioma (clinicaltrials.gov) - Mar 18, 2019
P2/3, N=545, Terminated, Sponsor: Boehringer Ingelheim
N=79 --> 0 | Not yet recruiting --> Withdrawn Phase classification: P3 --> P2/3 | Completed --> Terminated
- | Trial completion, Trial completion date: 11C-Metomidate PET Versus Adrenal Vein Sampling in Primary Aldosteronism (clinicaltrials.gov) - Mar 11, 2019
P=N/A, N=40, Completed, Sponsor: Helsinki University Central Hospital
Phase classification: P3 --> P2/3 | Completed --> Terminated Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2019
- | Trial completion: Chest Wall Motion Analysis in Disease (clinicaltrials.gov) - Feb 22, 2019
P=N/A, N=400, Completed, Sponsor: Heart of England NHS Trust
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2019 Recruiting --> Completed
- | CRS-207 / Novartis
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: KEYNOTE-701: Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) (clinicaltrials.gov) - Feb 19, 2019
P2, N=10, Terminated, Sponsor: Aduro Biotech, Inc.
Recruiting --> Completed N=35 --> 10 | Trial completion date: Mar 2019 --> Jan 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jan 2018; Study was stopped due to low enrollment and lack of clinical activity.
- | Trial completion, Trial primary completion date: Adenoma Detection by Polypectomy During Both Insertion and Withdrawal (clinicaltrials.gov) - Feb 12, 2019
P=N/A, N=1142, Completed, Sponsor: The Catholic University of Korea
N=35 --> 10 | Trial completion date: Mar 2019 --> Jan 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jan 2018; Study was stopped due to low enrollment and lack of clinical activity. Not yet recruiting --> Completed | Trial primary completion date: Aug 2015 --> Jul 2016
- | Trial completion date, Trial primary completion date: EC-Cap-SC: Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy (clinicaltrials.gov) - Feb 12, 2019
P=N/A, N=561, Completed, Sponsor: Helios Albert-Schweitzer-Klinik Northeim
Not yet recruiting --> Completed | Trial primary completion date: Aug 2015 --> Jul 2016 Trial completion date: Mar 2018 --> Feb 2019 | Trial primary completion date: Mar 2018 --> Feb 2019
- | TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry (clinicaltrials.gov) - Jan 31, 2019
P2, N=56, Completed, Sponsor: Center Eugene Marquis
Trial completion date: Mar 2018 --> Feb 2019 | Trial primary completion date: Mar 2018 --> Feb 2019 Active, not recruiting --> Completed | N=210 --> 56 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Mar 2018 --> Dec 2018
- | sirolimus / Generic mfg.
Trial completion: Sirolimus and Familial Adenomatous Polyposis (FAP) (clinicaltrials.gov) - Jan 28, 2019
P2, N=4, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Active, not recruiting --> Completed | N=210 --> 56 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Mar 2018 --> Dec 2018 Recruiting --> Completed
- | Biomarker, Trial termination: Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107 (clinicaltrials.gov) - Jan 24, 2019
P=N/A, N=47, Terminated, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed Active, not recruiting --> Terminated; Poor accrual
- sorafenib / Generic mfg.
Trial completion: Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. (clinicaltrials.gov) - Jan 19, 2019
P2, N=44, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Poor accrual Active, not recruiting --> Completed
- | Enrollment change, Trial withdrawal: A Study on Precutting Methods of Endoscopic Submucosal Dissection for Gastric Neoplasms Located at Lesser Curvature Side of Antrum (clinicaltrials.gov) - Jan 17, 2019
P=N/A, N=0, Withdrawn, Sponsor: Yonsei University
Active, not recruiting --> Completed N=86 --> 0 | Recruiting --> Withdrawn
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Enrollment change, Metastases: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (clinicaltrials.gov) - Jan 16, 2019
P2, N=137, Completed, Sponsor: MolMed S.p.A.
N=86 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed | N=100 --> 137
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program (clinicaltrials.gov) - Jan 11, 2019
P=N/A, N=52, Completed, Sponsor: Kantonsspital Winterthur KSW
Active, not recruiting --> Completed | N=100 --> 137 Recruiting --> Completed | N=88 --> 52 | Trial completion date: Jul 2018 --> Oct 2018 | Trial primary completion date: Jul 2018 --> Oct 2018
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: 18F-FSPG PET/CT for Cancer Patients on Therapy (clinicaltrials.gov) - Jan 3, 2019
P2, N=7, Completed, Sponsor: Andrei Iagaru
Recruiting --> Completed | N=88 --> 52 | Trial completion date: Jul 2018 --> Oct 2018 | Trial primary completion date: Jul 2018 --> Oct 2018 Suspended --> Completed | N=50 --> 7 | Trial completion date: Jul 2017 --> Dec 2016 | Trial primary completion date: Jul 2017 --> Dec 2016
- | everolimus / Generic mfg.
Trial completion, Trial primary completion date, Metastases: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus (clinicaltrials.gov) - Nov 8, 2018
P2, N=54, Completed, Sponsor: European Institute of Oncology
Suspended --> Completed | N=50 --> 7 | Trial completion date: Jul 2017 --> Dec 2016 | Trial primary completion date: Jul 2017 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> Jan 2017
- | Biomarker, Trial completion, Enrollment change, Trial primary completion date: Predictive Factors of Recurrence of Non Functioning Pituitary Adenomas : a Retrospective Study of 220 Patients in the Reims University Hospital, France (clinicaltrials.gov) - Oct 25, 2018
P=N/A, N=106, Completed, Sponsor: CHU de Reims
Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> Jan 2017 Recruiting --> Completed | N=220 --> 106 | Trial primary completion date: Mar 2017 --> Dec 2017
- | Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date: PACE4 in Thyroid Cancer (clinicaltrials.gov) - Oct 2, 2018
P=N/A, N=39, Completed, Sponsor: Robert Day
Recruiting --> Completed | N=220 --> 106 | Trial primary completion date: Mar 2017 --> Dec 2017 Enrolling by invitation --> Completed | N=30 --> 39 | Trial completion date: Oct 2017 --> Jan 2018 | Trial primary completion date: Jul 2017 --> Jan 2018
- | Trial completion: Does Cap Assisted Colonoscopy Improve Detection of Adenomatous Polyps? (CAP Trial) (clinicaltrials.gov) - Sep 26, 2018
P=N/A, N=1148, Completed, Sponsor: White River Junction Veterans Affairs Medical Center
Enrolling by invitation --> Completed | N=30 --> 39 | Trial completion date: Oct 2017 --> Jan 2018 | Trial primary completion date: Jul 2017 --> Jan 2018 Active, not recruiting --> Completed
- | carboplatin / Generic mfg., cisplatin / Generic mfg., pemetrexed / Generic mfg.
Trial completion, Combination therapy: Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) (clinicaltrials.gov) - Sep 25, 2018
P2, N=82, Completed, Sponsor: NovoCure Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| cisplatin / Generic mfg., pemetrexed / Generic mfg., nintedanib / Generic mfg.
Trial completion, Combination therapy, Monotherapy: LUME-Meso: Nintedanib (BIBF 1120) in Mesothelioma (clinicaltrials.gov) - Sep 11, 2018
P3, N=545, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion, Trial completion date, Trial primary completion date: B-ADENOMA: BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities (clinicaltrials.gov) - Sep 6, 2018
P=N/A, N=3221, Completed, Sponsor: South Tyneside NHS Foundation Trust
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Sep 2018 --> Feb 2018 | Trial primary completion date: Jul 2018 --> Feb 2018
- | Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (clinicaltrials.gov) - Aug 29, 2018
P2, N=100, Active, not recruiting, Sponsor: MolMed S.p.A.
Recruiting --> Completed | Trial completion date: Sep 2018 --> Feb 2018 | Trial primary completion date: Jul 2018 --> Feb 2018 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Dec 2018
- | Trial completion, Trial completion date, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Aug 22, 2018
P=N/A, N=235, Completed, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2015
- | Trial completion: Effectiveness and Safety of the Endoscopic Removal of Large and Flat Colonic Polyps With LumenR RetractorTM (clinicaltrials.gov) - Aug 21, 2018
P=N/A, N=60, Completed, Sponsor: Mercy Medical Center
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2015 Recruiting --> Completed
- | Trial completion, Trial completion date: VOLGACORE: Volatile Markers in Digestive Cancer (clinicaltrials.gov) - Aug 21, 2018
P=N/A, N=2022, Completed, Sponsor: University of Latvia
Recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2017
- | Trial completion: Effectiveness and Safety of the Colonoscopy With "Visualization" Balloon (clinicaltrials.gov) - Aug 21, 2018
P=N/A, N=216, Completed, Sponsor: Mercy Medical Center
Recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2017 Recruiting --> Completed
- | Omnicef (cefdinir) / Abbott
Trial completion date, Trial initiation date, Surgery: POET: Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions (clinicaltrials.gov) - Aug 15, 2018
P4, N=116, Recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Recruiting --> Completed Trial completion date: Mar 2019 --> Jul 2019 | Initiation date: Jan 2017 --> Jul 2017
- | Signifor LAR (pasireotide long acting release) / Recordati
Trial completion date, Trial primary completion date: Passion I: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (clinicaltrials.gov) - Aug 10, 2018
P2, N=20, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2019 --> Jul 2019 | Initiation date: Jan 2017 --> Jul 2017 Trial completion date: May 2016 --> Sep 2017 | Trial primary completion date: May 2016 --> Sep 2017
- | cisplatin / Generic mfg., pemetrexed / Generic mfg.
Trial completion, Trial completion date, Surgery: SAKK 17/04: Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma (clinicaltrials.gov) - Aug 7, 2018
P2, N=153, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Trial completion date: May 2016 --> Sep 2017 | Trial primary completion date: May 2016 --> Sep 2017 Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Jan 2018
- | SS1(dsFv)-PE38 / AstraZeneca
Trial termination: SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma (clinicaltrials.gov) - Aug 3, 2018
P1, N=24, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Jan 2018 Completed --> Terminated
- | Trial suspension, Surgery: TEMENDO: Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas (clinicaltrials.gov) - Jul 26, 2018
P4, N=120, Suspended, Sponsor: European Association for Endoscopic Surgery
Completed --> Terminated Recruiting --> Suspended
- | Trial completion, Trial completion date, Tumor cell: The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma (clinicaltrials.gov) - Jul 23, 2018
P=N/A, N=9, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Suspended Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Mar 2018
- | midazolam hydrochloride / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Metastases: NonAA: To Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas (clinicaltrials.gov) - Jul 10, 2018
P=N/A, N=828, Completed, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Mar 2018 Recruiting --> Completed | Trial completion date: Jun 2019 --> Jun 2018 | Trial primary completion date: Dec 2018 --> Jun 2018
- ||| cisplatin / Generic mfg., pemetrexed / Generic mfg., nintedanib / Generic mfg.
Trial completion date, Combination therapy, Monotherapy: LUME-Meso: Nintedanib (BIBF 1120) in Mesothelioma (clinicaltrials.gov) - Jun 14, 2018
P3, N=545, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | Trial completion date: Jun 2019 --> Jun 2018 | Trial primary completion date: Dec 2018 --> Jun 2018 Trial completion date: Oct 2019 --> Aug 2018
- | Photofrin (porfimer sodium) / Advanz Pharma
Trial completion, Trial completion date, Trial primary completion date: Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma (clinicaltrials.gov) - Jun 14, 2018
P2, N=6, Completed, Sponsor: University Hospital, Lille
Trial completion date: Oct 2019 --> Aug 2018 Recruiting --> Completed | Trial completion date: Jan 2019 --> Mar 2018 | Trial primary completion date: Jan 2019 --> Mar 2018
- || Signifor LAR (pasireotide long acting release) / Recordati
Trial completion: Passion I: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (clinicaltrials.gov) - Jun 2, 2018
P2, N=20, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial completion date: Jan 2019 --> Mar 2018 | Trial primary completion date: Jan 2019 --> Mar 2018 Recruiting --> Completed
- Oshadi D (DNase in Oshadi carrier) / Oshadi Drug Administration, Oshadi R (RNase in Oshadi carrier) / Oshadi Drug Administration
Trial suspension: Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment (clinicaltrials.gov) - Apr 18, 2018
P2a, N=17, Suspended, Sponsor: Oshadi Drug Administration
Recruiting --> Completed Not yet recruiting --> Suspended
- | Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence (clinicaltrials.gov) - Apr 13, 2018
P2/3, N=1061, Active, not recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Not yet recruiting --> Suspended Recruiting --> Active, not recruiting | N=200 --> 1061 | Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2017 --> Jun 2018
- | cixutumumab (IMC A12) / Eli Lilly
Trial completion: Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy (clinicaltrials.gov) - Apr 10, 2018
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=200 --> 1061 | Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2017 --> Jun 2018 Active, not recruiting --> Completed
- | Trial completion, Phase classification: Evaluation of Flexible Sigmoidoscopy Screening as an Adjunct to the National FOBT Screening Programme in Scotland (clinicaltrials.gov) - Mar 23, 2018
P=N/A, N=4567, Completed, Sponsor: University of Dundee
Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: P3 --> PN/A
- | Trial completion date, Trial primary completion date: SANO: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment (clinicaltrials.gov) - Mar 21, 2018
P3, N=180, Not yet recruiting, Sponsor: Medical University of Vienna
Recruiting --> Completed | Phase classification: P3 --> PN/A Trial completion date: Jan 2024 --> Oct 2024 | Trial primary completion date: Jan 2023 --> Oct 2023
- | Trial completion: Comparison of ADR Using NBI Versus HD White Light Colonoscopy in Screening and Surveillance Colonoscopies (clinicaltrials.gov) - Mar 20, 2018
P=N/A, N=500, Completed, Sponsor: Jena University Hospital
Trial completion date: Jan 2024 --> Oct 2024 | Trial primary completion date: Jan 2023 --> Oct 2023 Recruiting --> Completed